ASCO's Top 5 Oncology List

LISA SCHULMEISTER, RN, MN, APRN-BC, OCN, FAAN
Thursday, November 07, 2013
Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
In 2012, the American Society of Clinical Oncology (ASCO) participated in the American Board of Medicine Foundation’s Choosing Wisely Campaign, which sought to identify tests and procedures that offer little or no benefit to patients. ASCO elicited current committee members to offer suggestions for a 2013 list of these tests and procedures, and removed duplicates, researched the literature, and used its Value in Cancer Task Force to trim the list to 11 items, which were then voted upon by ASCO’s leadership.

The 2013 top 5 list includes:
  1. Overmedicating for nausea: patients receiving chemotherapy regimens with a low or moderate emetogenic risk should not receive antiemetics intended for use with a regimen that has a high emetogenic risk.
  2. Overuse of chemotherapy: multiple drug regimens should not be used to treat metastatic breast cancer when one drug regimens have similar outcomes and lower cost (the exception is when the patient requires a rapid response to relieve tumor-related symptoms).
  3. Inappropriate use of imaging tests: PET and PET-CT scanning should not be used to routinely monitor patients after initial treatment, unless there is high-level evidence that PET or PET-CT imaging will change the outcome.
  4. Unwarranted screening: PSA testing should not be performed for prostate cancer screening in men with no symptoms and a life expectancy of less than 10 years.
  5. Misuse of treatments: targeted therapy intended for use against a specific genetic aberration should not be used unless the patient’s tumor cells have the specific biomarker that predicts an effective response to the targeted therapy.
Reference
Schnipper LE, Lyman GH, Blayney DW, et al. American Society of Clinical Oncology 2013 top five list in oncology. J Clin Oncol 2013; published ahead of print on 10/29/13 as 10.1200/JCO.2013.53.3943.


Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN
 
Blog Info
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN is an oncology nursing consultant and editor-in-chief of Oncology Nursing News.
Author Bio
Lisa Schulmeister, MN, RN, ACNS-BC, FAAN, is the Editor-in-Chief for OncLive Nursing. She is an oncology nursing consultant and adjunct assistant professor of nursing at Louisiana State Health Sciences Center in New Orleans, LA. She provides continuing nursing education to nurses across the Unites States, is active in several professional nursing organizations, and is intrigued by the many ways nurses use technology to communicate.
 
 
External Resources

MJH Associates
American Journal of Managed Care
Cure
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
TargetedOnc
OncNurse Resources

Blogs
Continuing Education
Discussions
Web Exclusives


About Us
Advertise
Advisory Board
Careers
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2017
Intellisphere, LLC. All Rights Reserved.